References
- Hozé N, Paireau J, Lapidus N, et al. Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. Lancet Public Health. 2021;6(6):e408–9. DOI:10.1016/S2468-2667(21)00064-5
- Salje H, Tran Kiem C, Lefrancq N. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369(6500):208–211. DOI:10.1126/science.abc3517
- Agence Technique de l’Information sur l’Hospitalisation. Guide de l’Etude Nationale de Coûts. Paris: ATIH; 2020.
- Joannes-Boyau O, Dahyot-Fizelier C, Albaladejo P. Lack of vaccination in ventilated patients for SARS-CoV-2 in France. Anaesth Crit Care Pain Med. 2022;41(2):101021.
- Naouri D, Vuagnat A, Beduneau G. Covid-19 : prise en charge des patients en soins critiques au cours des trois premières vagues de l’épidémie. Etudes et résultats. 2022;1226:1–8.
- L’Assurance Maladie, Améliorer la qualité du système de santé et maîtriser les dépenses : propositions de l’assurance maladie pour 2022. 2021.
- Ministre de l’Économie des Finances et de la Souveraineté industrielle et numérique. Projet de loi de financement de la sécurité sociale pour 2023; 2020. https://assurance-maladie.ameli.fr/sites/default/files/2021-07_rapport-propositions-pour-2022_assurance-maladie_3.pdf
- Naouri D. En 2020, le nombre de séjours hospitaliers hors Covid-19 a diminué de 13 % par rapport à 2019. Etudes et résultats. 2021;1204:1–8.
- L’Assurance Maladie. Améliorer la qualité du système de santé et maîtriser les dépenses : propositions de l’assurance maladie pour 2023; 2022. https://assurance-maladie.ameli.fr/sites/default/files/2022-07_rapport-propositions-pour-2023_assurance-maladie_1.pdf
- Tuppin P, Rivière S, Rigault A, et al. Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database. Arch Cardiovasc Dis. 2016;109(6–7):399–411. DOI:10.1016/j.acvd.2016.01.011
- Dupuis C, Sabra A, Patrier J, et al. Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs. crit care. 2021;25(1):24. DOI:10.1186/s13054-020-03442-z
- Pivette M, Nicolay N, Lauzun V, et al. Characteristics of hospitalizations with an influenza diagnosis, France, 2012-2013 to 2016-2017 influenza seasons. Influenza Other Respir Viruses. 2020;14(3):340–348. DOI:10.1111/irv.12719
- Santé Publique France. COVID-19 : Point épidémiologique hebdomadaire du 31 décembre 2020. Saint Maurice; 2020. https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-31-decembre-2020
- Rentsch CT, Beckman, J. A., Tomlinson, L., Gellad, W. F., Alcorn, C., Kidwai-Khan, F., & Freiberg, M. S. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021;372:n311.
- Tacquard C, Mansour, A., Godon, A., Godet, J., Poissy, J., Garrigue, D., & Zufferey, P. Impact of high-dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia. Chest. 2021;159(6):2417–2427. DOI:10.1016/j.chest.2021.01.017
- Pulakurthi YS, Pederson, J. M., Saravu, K., Gupta, N., Balasubramanian, P., Kamrowski, S., & Evanson, K. W. Corticosteroid therapy for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021;100(20):e25719. DOI:10.1097/MD.0000000000025719
- van Paassen J, Vos JS, Hoekstra EM, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. crit care. 2020;24(1):696. DOI:10.1186/s13054-020-03400-9
- Hermine O, Mariette X, Tharaux P-L, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32–40. DOI:10.1001/jamainternmed.2020.6820
- Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–2344. DOI:10.1056/NEJMoa2028836
- Corti D, Purcell, L. A., Snell, G., & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086–3108. DOI:10.1016/j.cell.2021.05.005
- Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–393. DOI:10.1038/s41577-021-00542-x
- Tetro JA. From hidden outbreaks to epidemic emergencies: the threat associated with neglecting emerging pathogens. Microbes Infect. 2019;21(1):4–9.
- Lefrançois T, Malvy D, Atlani-Duault L, et al. After 2 years of the COVID-19 pandemic, translating one health into action is urgent. Lancet. 2022; DOI:10.1016/S0140-6736(22)01840-2.